Avicena Group, Inc.

Neurosearch's novel therapy Huntexil (pridopidine) met its primary endpoint, improving motor function in a Phase III Huntington's study, show top-line results. Excited investors drove the share price

Pfizer and Medivation have started a Phase III trial to test Dimebon (latrepirdine) as a treatment for Huntington's disease. Pfizer licensed rights to develop and commercialise the drug for Alzheimer'

Medivation's investigational drug Dimebon, whose most advanced indication is Alzheimer's disease, improves cognitive function in patients with Huntington's disease and is safe and well-tolerated, top-

Tracking and treating diseases via the "other" human genome. A few years ago, when Robert Davis, PhD, the president and chief scientific officer of MitoKor Inc. (then called Applied Genetics Inc.)